Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivaroxaban versus enoxaparin for prevention of deep vein thrombosis in pelvic fracture
IRCT20190120042419N1Phase 3Completed
- Sponsor
- Iran University of Medical Sciences
- Start
- Jan 2019
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 3, double-blind trial of rivaroxaban and enoxaparin in pelvic fracture (2 arms), sponsored by Iran University of Medical Sciences. Primary endpoints: Deep venous thrombosis, Abnormal bleeding and 3 more. Started Jan 2019; status: completed.
02
Drugs
rivaroxabanenoxaparin
03
Conditions
pelvic fracture
Beyond the preview
Go deeper on IRCT20190120042419N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20190120042419N1.